{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T01:34:37Z","timestamp":1792028077728,"version":"4.4.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"7","license":[{"start":{"date-parts":[[2024,6,20]],"date-time":"2024-06-20T00:00:00Z","timestamp":1718841600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n                    <jats:title>Background.<\/jats:title>\n                    <jats:p>Solid organ transplant (SOT) candidates should be screened and treated for latent tuberculosis infection (LTBI) to prevent tuberculosis (TB) reactivation after transplantation. We aimed to assess the steps from positive QuantiFERON (QFT) through LTBI treatment (cascade of care) in the SOT population.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods.<\/jats:title>\n                    <jats:p>We conducted a retrospective study of SOT recipients older than 18 y with a positive QFT during pretransplant evaluation at the Mayo Clinic from January 2010 to June 2023. We analyzed each cascade step to determine associated drop-out factors for LTBI management.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results.<\/jats:title>\n                    <jats:p>Of 629 patients who had positive QFT results, 587 (93%) were evaluated by an infectious disease (ID) specialist, 478 (76%) were recommended to start LTBI treatment, 473 (75%) initiated LTBI treatment, and 457 (73%) completed LTBI treatment. LTBI treatment was not recommended in 109 patients evaluated by infectious disease, most of whom had previously received either LTBI (n = 72) or TB (n = 14) treatment. LTBI treatment was initiated before or after transplantation for 45% and 55% of patients, respectively. Isoniazid monotherapy was the most common regimen (92%), and adverse events were rare (7%). Seven patients developed active TB infection posttransplantation under various circumstances (3 without LTBI treatment, 1 during LTBI treatment, and 3 after completing LTBI treatment).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions.<\/jats:title>\n                    <jats:p>Our findings demonstrate the variability of LTBI management in SOT recipients with positive QFT. When recommended, most patients completed LTBI treatment successfully. Nonetheless, active TB was noted regardless of whether patients received LTBI treatment. This study highlights the importance of optimizing LTBI management in this population.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1097\/txd.0000000000001672","type":"journal-article","created":{"date-parts":[[2024,6,21]],"date-time":"2024-06-21T00:04:17Z","timestamp":1718928257000},"page":"e1672","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":5,"title":["The Cascade of Care in Management of Solid Organ Transplant Candidates With Latent Tuberculosis Infection"],"prefix":"10.1097","volume":"10","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5241-3435","authenticated-orcid":false,"given":"Chia-Yu","family":"Chiu","sequence":"first","affiliation":[{"name":"Division of Public Health, Infectious Diseases, and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maryam","family":"Mahmood","sequence":"additional","affiliation":[{"name":"Division of Public Health, Infectious Diseases, and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, MN."},{"name":"William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa M.","family":"Brumble","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic, Jacksonville, FL."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Holenarasipur R.","family":"Vikram","sequence":"additional","affiliation":[{"name":"Division of Infectious Diseases, Mayo Clinic, Phoenix, AZ."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elitza S.","family":"Theel","sequence":"additional","affiliation":[{"name":"Division of Clinical Microbiology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Beam","sequence":"additional","affiliation":[{"name":"Division of Public Health, Infectious Diseases, and Occupational Medicine, Department of Medicine, Mayo Clinic, Rochester, MN."},{"name":"William J. von Liebig Center for Transplantation and Clinical Regeneration, Mayo Clinic, Rochester, MN."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2024,6,20]]},"reference":[{"key":"R1-20240805","doi-asserted-by":"crossref","first-page":"1657","DOI":"10.1086\/599035","article-title":"Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort.","volume":"48","author":"Torre-Cisneros","year":"2009","journal-title":"Clin Infect Dis"},{"key":"R2-20240805","doi-asserted-by":"crossref","first-page":"e13513","DOI":"10.1111\/ctr.13513","article-title":"Mycobacterium tuberculosis infections in solid organ transplantation: guidelines from the infectious diseases community of practice of the American Society of Transplantation.","volume":"33","author":"Subramanian","year":"2019","journal-title":"Clin Transplant"},{"key":"R3-20240805","doi-asserted-by":"crossref","first-page":"ofad324","DOI":"10.1093\/ofid\/ofad324","article-title":"Screening for latent tuberculosis infection in solid organ transplant recipients to predict active disease: a systematic review and meta-analysis of diagnostic studies.","volume":"10","author":"Yahav","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"R4-20240805","doi-asserted-by":"crossref","first-page":"e13548","DOI":"10.1111\/ctr.13548","article-title":"Screening of donor and candidate prior to solid organ transplantation\u2014guidelines from the American Society of Transplantation Infectious Diseases Community of Practice.","volume":"33","author":"Malinis","year":"2019","journal-title":"Clin Transplant"},{"key":"R5-20240805","doi-asserted-by":"crossref","first-page":"e13999","DOI":"10.1111\/tid.13999","article-title":"The cascade of care in testing and treatment of latent tuberculosis infection in liver transplant candidates.","volume":"25","author":"Foppiano Palacios","year":"2023","journal-title":"Transpl Infect Dis"},{"key":"R6-20240805","article-title":"Latent TB infection testing and treatment summary of U.S. recommendations."},{"key":"R7-20240805","doi-asserted-by":"crossref","first-page":"1","DOI":"10.15585\/mmwr.rr6901a1","article-title":"Guidelines for the treatment of latent tuberculosis infection: recommendations from the National Tuberculosis Controllers Association and CDC, 2020.","volume":"69","author":"Sterling","year":"2020","journal-title":"MMWR Recomm Rep"},{"key":"R8-20240805","article-title":"QuantiFERON-TB Gold Plus (QFT-Plus). Package insert."},{"key":"R9-20240805","article-title":"Package insert."},{"key":"R10-20240805","article-title":"Tuberculin skin testing fact sheet."},{"key":"R11-20240805","article-title":"WHO global lists of high burden countries for tuberculosis (TB), TB\/HIV and multidrug\/rifampicin resistant TB (MDR\/RR-TB), 2021\u20132025."},{"key":"R12-20240805","article-title":"TB risk factors."},{"key":"R13-20240805","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1016\/S1473-3099(16)30216-X","article-title":"The cascade of care in diagnosis and treatment of latent tuberculosis infection: a systematic review and meta-analysis.","volume":"16","author":"Alsdurf","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"R14-20240805","doi-asserted-by":"crossref","first-page":"100","DOI":"10.5588\/ijtld.19.0185","article-title":"Interventions to reduce losses in the cascade of care for latent tuberculosis: a systematic review and meta-analysis.","volume":"24","author":"Barss","year":"2020","journal-title":"Int J Tuberc Lung Dis"},{"key":"R15-20240805","article-title":"Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV."},{"key":"R17-20240805","first-page":"77","article-title":"Chapter 6: tuberculosis preventive treatment in adults.","volume":"6","author":"Alvarez","year":"2022","journal-title":"Canad J Respirat Crit Care Sleep Med"},{"key":"R18-20240805","doi-asserted-by":"crossref","first-page":"e0137021","DOI":"10.1128\/JCM.01370-21","article-title":"The impact of borderline Quantiferon-TB Gold Plus results for latent tuberculosis screening under routine conditions in a low-endemicity setting.","volume":"59","author":"Wikell","year":"2021","journal-title":"J Clin Microbiol"},{"key":"R19-20240805","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1016\/j.jmii.2023.07.014","article-title":"Predicting stringent QuantiFERON-TB Gold Plus conversions in contacts of tuberculosis patients.","volume":"56","author":"Pan","year":"2023","journal-title":"J Microbiol Immunol Infect"},{"key":"R20-20240805","first-page":"1","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection. American Thoracic Society.","volume":"49","author":"Lawrence","year":"2000","journal-title":"MMWR Recomm Rep"},{"key":"R21-20240805","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1056\/NEJMoa1806808","article-title":"One month of rifapentine plus isoniazid to prevent HIV-related tuberculosis.","volume":"380","author":"Swindells","year":"2019","journal-title":"N Engl J Med"},{"key":"R22-20240805","doi-asserted-by":"crossref","first-page":"e13178","DOI":"10.1111\/tid.13178","article-title":"Treatment of latent TB Infection and the risk of tuberculosis after solid organ transplantation: comprehensive review.","volume":"21","author":"Abad","year":"2019","journal-title":"Transpl Infect Dis"},{"key":"R23-20240805","doi-asserted-by":"crossref","first-page":"e13259","DOI":"10.1111\/ctr.13259","article-title":"Mycobacterium tuberculosis after solid organ transplantation: a review of more than 2000 cases.","volume":"32","author":"Abad","year":"2018","journal-title":"Clin Transplant"}],"container-title":["Transplantation Direct"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001672","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,5]],"date-time":"2024-08-05T00:03:11Z","timestamp":1722816191000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/TXD.0000000000001672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,20]]},"references-count":22,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2024]]}},"URL":"https:\/\/doi.org\/10.1097\/txd.0000000000001672","relation":{},"ISSN":["2373-8731"],"issn-type":[{"value":"2373-8731","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,20]]}}}